RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ARGX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

argenx SE stock price down 1.22% on Thursday
(Updated on Mar 28, 2024)

Sell candidate since Mar 25, 2024 Loss -1.18% PDF

The argenx SE stock price fell by -1.22% on the last day (Thursday, 28th Mar 2024) from $398.59 to $393.72. During the last trading day the stock fluctuated 1.55% from a day low at $391.70 to a day high of $397.79. The price has fallen in 7 of the last 10 days but is still up by 3.98% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -59 thousand shares and in total, 184 thousand shares were bought and sold for approximately $72.52 million.

The stock is moving within a wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect argenx SE stock with a 90% probability to be traded between $362.79 and $424.98 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ARGX Signals & Forecast

The argenx SE stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $392.12 and $390.63. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Friday, March 22, 2024, and so far it has fallen -2.23%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for argenx SE stock

argenx SE finds support from accumulated volume at $381.27 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $6.09 between high and low, or 1.55%. For the last week, the stock has had daily average volatility of 2.18%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ARGX) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect argenx SE to open at $394.40, and during the day (based on 14 day Average True Range), to move between $381.94 and $405.50, which gives a possible trading interval of +/-$11.78 (+/-2.99%) up or down from last closing price. If argenx SE takes out the full calculated possible swing range there will be an estimated 5.98% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $396.22 (0.63%) than the support at $381.27 (3.16%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is argenx SE stock A Buy?

argenx SE holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.642 Sell Candidate Unchanged

Predicted Opening Price for argenx SE of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$394.40 ( 0.174%) $393.72

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ARGX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 400.49 1.72 %
R2 398.17 1.13 %
R1 396.73 0.764 %
Current price: 393.72
Support S1 392.08 -0.417 %
S2 390.64 -0.782 %
S3 388.31 -1.37 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 403.37 2.45 %
R2 396.88 0.80 %
R1 396.22 0.635 %
Current price 393.72
Support S1 381.27 -3.16%
S2 380.01 -3.48%
S3 364.53 -7.41%

FAQ

What is the symbol for argenx SE Stock and on which exchange is it traded?
The symbol for argenx SE is ARGX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell argenx SE Stock?
argenx SE holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy argenx SE Stock?
argenx SE Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy argenx SE Stock.

What's the current price of argenx SE Stock?
As of the end of day on the 2024-03-28, the price of an argenx SE (ARGX) share was $393.72.

What is the 52-week high and low for argenx SE Stock?
The 52-week high for argenx SE Stock is $550.76 and the 52-week low is $327.73.

What is the market capitalization of argenx SE Stock?
As of the 2024-03-28, the market capitalization of argenx SE is 23.348B.

When is the next earnings date for argenx SE?
The upcoming earnings date for argenx SE is May 02, 2024.
Click to get the best stock tips daily for free!

About argenx SE

argenx SE argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid ... ARGX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT